French pharmaceutical lobby pushes for health sovereignty

The five major French pharmaceutical companies, represented by G5 Santé, are advocating for health sovereignty as a strategic priority ahead of the 2027 Social Security Financing Bill and the presidential election. This group includes well-known names such as Sanofi, Servier, and Pierre-Fabre.

G5 Santé highlights regulatory challenges

Two studies commissioned by G5 Santé reveal that the sector faces increasing regulatory burdens and that more than half of the medical treatments approved in Europe are not accessible in France. These findings aim to inform the upcoming presidential election debate on healthcare policy.

Lobby calls for reform proposals

G5 Santé is pushing for reforms such as a temporary halt on price reductions for medications. The group emphasizes its commitment to "made in France" production while urging policymakers to address barriers to medical innovation and access.

Studies target presidential candidates

The studies published by G5 Santé are intended to raise awareness among presidential candidates about the challenges in accessing medical innovations in France. The group hopes to influence the future direction of healthcare policy in the country.

Photo credit provided

The image accompanying the report is credited to Sébastien Toubon, a photographer known for capturing moments in French public life and policy discussions.